Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies

BACKGROUND: The use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugwu, David I., Okoro, Uchechukwu C., Mishra, Narendra K., Okafor, Sunday N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964670/
https://www.ncbi.nlm.nih.gov/pubmed/29789011
http://dx.doi.org/10.1186/s12944-018-0764-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964670/
https://www.ncbi.nlm.nih.gov/pubmed/29789011
http://dx.doi.org/10.1186/s12944-018-0764-y

Ejemplares similares